Literature DB >> 8882078

Mortality rates from cryptogenic fibrosing alveolitis in seven countries.

R Hubbard1, I Johnston, D B Coultas, J Britton.   

Abstract

BACKGROUND: Registered mortality from cryptogenic fibrosing alveolitis (CFA) in England and Wales has increased substantially since the specific International Classification of Diseases code for CFA was introduced in 1979. However, since a significant proportion of deaths from CFA are misclassified as post inflammatory fibrosis (PIF), it is possible that the observed rise in CFA mortality is due to diagnostic transfer from this code. To investigate this, and to assess mortality trends in other countries, annual CFA and PIF mortality data from England and Wales, USA, Australia, Scotland, Canada, New Zealand, and Germany were analysed.
METHODS: Crude annual mortality rates were calculated and rates standardised by Poisson regression to allow assessment of changes over time and comparison between countries, sexes, and age groups. The relative trends in mortality from CFA and PIF were assessed by calculating the annual ratio of CFA to PIF deaths.
RESULTS: Men were more likely than women to die from both CFA and PIF in all countries. The highest standardised CFA mortality rate occurred in England and Wales, and the lowest in Germany. Since 1979 mortality from CFA has increased in England and Wales, Australia, Scotland and Canada, but there was no trend in CFA mortality in New Zealand or Germany. In the USA mortality from CFA was low and has fallen. Mortality from PIF increased in all countries except New Zealand and Germany, and the highest PIF mortality, together with the greatest increase over time, was seen in the USA. Changes over time in the annual ratio of CFA to PIF deaths in all countries were small, implying that diagnostic transfer is not a major cause of the increasing CFA mortality.
CONCLUSIONS: Mortality from CFA continues to increase in England and Wales and in many other countries. Diagnostic transfer from PIF does not appear to be a major cause of this.

Entities:  

Mesh:

Year:  1996        PMID: 8882078      PMCID: PMC472494          DOI: 10.1136/thx.51.7.711

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  15 in total

1.  Interstitial lung disease and domestic wood burning.

Authors:  J E Ramage; V L Roggli; D Y Bell; C A Piantadosi
Journal:  Am Rev Respir Dis       Date:  1988-05

2.  The epidemiology of interstitial lung diseases.

Authors:  D B Coultas; R E Zumwalt; W C Black; R E Sobonya
Journal:  Am J Respir Crit Care Med       Date:  1994-10       Impact factor: 21.405

3.  Pulmonary fibrosis in an aluminum arc welder.

Authors:  V Vallyathan; W N Bergeron; P A Robichaux; J E Craighead
Journal:  Chest       Date:  1982-03       Impact factor: 9.410

4.  Natural history and treated course of usual and desquamative interstitial pneumonia.

Authors:  C B Carrington; E A Gaensler; R E Coutu; M X FitzGerald; R G Gupta
Journal:  N Engl J Med       Date:  1978-04-13       Impact factor: 91.245

5.  Cryptogenic fibrosing alveolitis: assessment by graded trephine lung biopsy histology compared with clinical, radiographic, and physiological features.

Authors:  P H Wright; B E Heard; S J Steel; M Turner-Warwick
Journal:  Br J Dis Chest       Date:  1981-01

6.  Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival.

Authors:  M Turner-Warwick; B Burrows; A Johnson
Journal:  Thorax       Date:  1980-08       Impact factor: 9.139

7.  What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust.

Authors:  J Scott; I Johnston; J Britton
Journal:  BMJ       Date:  1990-11-03

8.  Rapidly fatal progression of cobalt lung in a diamond polisher.

Authors:  B Nemery; J Nagels; E Verbeken; D Dinsdale; M Demedts
Journal:  Am Rev Respir Dis       Date:  1990-05

9.  Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis.

Authors:  M A Johnson; S Kwan; N J Snell; A J Nunn; J H Darbyshire; M Turner-Warwick
Journal:  Thorax       Date:  1989-04       Impact factor: 9.139

10.  Occupational lung fibrosis in an aluminium polisher.

Authors:  P De Vuyst; P Dumortier; F Rickaert; R Van de Weyer; C Lenclud; J C Yernault
Journal:  Eur J Respir Dis       Date:  1986-02
View more
  21 in total

Review 1.  Review of cryptogenic fibrosing alveolitis, including current treatment guidelines.

Authors:  S C Bourke; H Clague
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 2.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  The burden of lung disease.

Authors:  R Hubbard
Journal:  Thorax       Date:  2006-07       Impact factor: 9.139

4.  Influence of sex and disease severity on gene expression profiles in individuals with idiopathic pulmonary fibrosis.

Authors:  Sean P McGee; Hongmei Zhang; Wilfried Karmaus; Tara Sabo-Attwood
Journal:  Int J Mol Epidemiol Genet       Date:  2014-05-29

5.  Adult height and cryptogenic fibrosing alveolitis: a case-control study using the UK general practice research database.

Authors:  R Hubbard; A Venn
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

6.  British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society.

Authors:  I D Johnston; R J Prescott; J C Chalmers; R M Rudd
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

7.  Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease.

Authors:  D B Sprunger; A L Olson; T J Huie; E R Fernandez-Perez; A Fischer; J J Solomon; K K Brown; J J Swigris
Journal:  Eur Respir J       Date:  2011-07-07       Impact factor: 16.671

8.  Specialist palliative care is more than drugs: a retrospective study of ILD patients.

Authors:  Sabrina Bajwah; Irene J Higginson; Joy R Ross; Athol U Wells; Surinder S Birring; Amit Patel; Julia Riley
Journal:  Lung       Date:  2012-01-05       Impact factor: 2.584

9.  Accuracy of mortality data for interstitial lung diseases in New Mexico, USA.

Authors:  D B Coultas; M P Hughes
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

10.  Capsaicin induced cough in cryptogenic fibrosing alveolitis.

Authors:  M J Doherty; R Mister; M G Pearson; P M Calverley
Journal:  Thorax       Date:  2000-12       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.